Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences, Inc. (GILD) filed a Form 4 on 07/01/2025 reporting that Chairman & CEO Daniel P. O’Day executed two open-market sales of the company’s common stock on 06/30/2025.
- Shares sold: 9,400 shares at a weighted-average price of $110.4038 and 600 shares at $111.1467, for a total of 10,000 shares.
- Remaining holdings: O’Day now directly owns 615,725 shares, down from 625,725, a reduction of roughly 1.6%.
- Trading plan: Transactions were carried out under a Rule 10b5-1 trading plan adopted on 02/28/2025, indicating pre-scheduled, automated execution.
- Price ranges: The first tranche was executed between $110.03 and $111.00; the second between $111.03 and $111.17. Detailed breakdowns are available upon request.
- No derivative securities or additional insider transactions were reported in this filing.
The filing signals continued, but limited, share disposition by the CEO within a structured trading program. Because the sale represents a small percentage of his total ownership and was executed under a 10b5-1 plan, the market impact is likely modest and largely informational rather than strategic.